A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches
Tekijät: Niiranen TJ, Vasan RS
Kustantaja: TAYLOR & FRANCIS INC
Julkaisuvuosi: 2016
Journal: Expert Review of Cardiovascular Therapy
Tietokannassa oleva lehden nimi: EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Lehden akronyymi: EXPERT REV CARDIOVAS
Vuosikerta: 14
Numero: 7
Aloitussivu: 855
Lopetussivu: 869
Sivujen määrä: 15
ISSN: 1477-9072
DOI: https://doi.org/10.1080/14779072.2016.1176528
Tiivistelmä
Introduction: Cardiovascular (CVD) risk assessment with traditional risk factors (age, sex, blood pressure, lipids, smoking and diabetes) has remained relatively invariant over the past decades despite some inaccuracies associated with this approach. However, the search for novel, robust and cost-effective risk markers of CVD risk is ongoing.Areas covered: A large share of the major developments in CVD risk prediction during the past five years has been made in large-scale biomarker discovery and the so called 'omics' - the rapidly growing fields of genomics, transcriptomics, epigenetics and metabolomics. This review focuses on how these new technologies are helping drive primary CVD risk estimation forward in recent years, and speculates on how they could be utilized more effectively for discovering novel risk factors in the future.Expert commentary: The search for new CVD risk factors is currently undergoing a significant revolution as the simple relationship between single risk factors and disease will have to be replaced by models that strive to integrate the whole field of omics into medicine.
Introduction: Cardiovascular (CVD) risk assessment with traditional risk factors (age, sex, blood pressure, lipids, smoking and diabetes) has remained relatively invariant over the past decades despite some inaccuracies associated with this approach. However, the search for novel, robust and cost-effective risk markers of CVD risk is ongoing.Areas covered: A large share of the major developments in CVD risk prediction during the past five years has been made in large-scale biomarker discovery and the so called 'omics' - the rapidly growing fields of genomics, transcriptomics, epigenetics and metabolomics. This review focuses on how these new technologies are helping drive primary CVD risk estimation forward in recent years, and speculates on how they could be utilized more effectively for discovering novel risk factors in the future.Expert commentary: The search for new CVD risk factors is currently undergoing a significant revolution as the simple relationship between single risk factors and disease will have to be replaced by models that strive to integrate the whole field of omics into medicine.
Turun yliopiston Tutkimustietojärjestelmän portaali